In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Quiz|Articles|August 14, 2026
OncLive Weekly News Quiz (8/14/2026): Did You Catch This Week's Myeloma, Lung Cancer, and Polycythemia Vera Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to iberdomide (Zenbexus) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma, based on data from the phase 3 EXCALIBER-RRMM trial (NCT04975997). What class of agent is iberdomide?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Read a refresh of GI cancer FDA news from July 2026, including an NDA acceptance for a RAS(ON) inhibitor in pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dr Banerjee on the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Dr Carlino on 5-Year Data With Intismeran Plus Pembrolizumab in Resected Melanoma
4
Dr Garg on a Phase 3 Study of Proton Therapy in Head and Neck Cancer
5